Antibodies to thrombomodulin are found in patients with lupus anticoagulant and unexplained thrombosis

Journal of Rheumatology

Volumn 27, Issue 2, 2000, Pages 384-390

  Carson, Craig W ^b   Comp, Philip C ^b   Rezaie, Alireza R ^b   Esmon, Naomi L ^b   Esmon, Charles T ^a  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^b NONE

Author keywords

Antibodies; Endothelium; Lupus Anticoagulant; Thrombomodulin; Thrombosis

Indexed keywords

LUPUS ANTICOAGULANT; THROMBOMODULIN;

ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HYPOTHESIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; THROMBOSIS;

ADULT; AGED; ANTIBODIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LUPUS COAGULATION INHIBITOR; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; THROMBOMODULIN; THROMBOSIS;

EID: 0033954611     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Petri M. The clinical syndrome associated with antiphospholipid antibodies. J Rheumatol 1992;19:505-7.
2. Esmon CT. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 1989;264:4743-6.
3. Ohlin AK, Marlar RA. The first mutation identified in the thrombomodulin gene in a 45-year-old man presenting with thromboembolic disease. Blood 1995;85:330-6.
4. Esmon CT. Protein S and protein C. Biochemistry, physiology, and clinical manifestations of deficiencies. Trends Cardiovasc Med 1992;2:214-9.
5. Bertina RM, Koeleman BPC, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-7.
6. Conard J, Bauer KA, Gruber A, et al. Normalization of markers of coagulation activation with a purified protein C concentrate in adults with homozygous protein C deficiency. Blood 1993; 82:1159-64.
7. Carreras LO, Forastiero RR. Pathogenic role of antiprotein-phospholipid antibodies. Haemostasis 1996;26:340-57.
8. Cariou R, Tobelem G, Bellucci S, et al. Effect of lupus anticoagulant on antithrombogenic properties of endothelial cells inhibition of thrombomodulin-dependent protein C activation. Thromb Haemost 1988;60:54-8.
9. Kellum A, Esmon CT, Comp PC. Anti-protein C activating activity and anti-phospholipid activity are separable [abstract]. Blood 1989;74:293.
10. Freyssinet J, Wiesel M, Gauchy J, Boneu B, Cazenave J. An IgM lupus anticoagulant that neutralizes the enhancing effect of phospholipid on purified endothelial thrombomodulin activity - A mechanism for thrombosis. Thromb Haemost 1986;55:309-13.
11. Ruiz-Arguelles GJ, Ruiz-Arguelles A, Deleze M, Alarcon-Segovia D. Acquired protein C deficiency in a patient with primary antiphospholipid syndrome. Relationship to reactivity of anticardiolipin antibody with thrombomodulin. J Rheumatol 1989;16:381-3.
12. Tsakiris DA, Settas L, Makris PE, Marbet GA. Lupus anticoagulant - antiphospholipid antibodies and thrombophilia. Relation to protein C-protein S-thrombomodulin. J Rheumatol 1990;17:785-9.
13. Gibson J, Nelson M, Brown R, Salem H, Kronenberg H. Autoantibodies to thrombomodulin: development of an enzyme immunoassay and a survey of their frequency in patients with the lupus anticoagulant. Thromb Haemost 1992;67:507-9.
14. Oosting JD, Preissner KT, Derksen RHWM, DeGroot PG. Autoantibodies directed against the epidermal growth factor-like domains of thrombomodulin inhibit protein C activation in vitro. Br J Haematol 1993;5:761-8.
15. Asherson RA, Khamashta MA, Ordi-Ros J, et al. The "primary" antiphospholipid syndrome: major clinical and serological features. Medicine 1989;68:366-74.
16. Asherson RA, Cervera R. The antiphospholipid syndrome: a syndrome in evolution. Ann Rheum Dis 1992;51:147-50.
17. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
18. Liu LW, Rezaie AR, Carson CW, Esmon NL, Esmon CT. Occupancy of anion binding exosite 2 on thrombin determines Ca2+ dependence of protein C activation. J Biol Chem 1994;269:11807-12.
19. Laszik Z, Carson CW, Nadasdy T, et al. Lack of suppressed renal thrombomodulin expression in a septic rat model with glomerular thrombotic microangiopathy. Lab Invest 1994;70:862-7.
20. Suzuki K, Kusumoto H. Deyashiki Y, et al. Structure and expression of human thrombomodulin, a thrombin receptor on endothelium acting as a cofactor for protein C activation. EMBO J 1987;6:1891-7.
21. Rezaie AR, Esmon CT. The function of calcium in protein C activation by thrombin and the thrombin-thrombomodulin complex can be distinguished by mutational analysis of protein C derivatives. J Biol Chem 1992;267:26104-9.
22. Rezaie AR, Fiore MM, Neuenschwander PF, Esmon CT, Morrissey JH. Expression and purification of a soluble tissue factor fusion protein with an epitope for an unusual calcium-dependent antibody. Protein Expr Purif 1992;3:453-60.
23. Laemmli UK. Cleavage proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-5.
24. Harris EN, Phil M. The Second International Anticardiolipin Standardization Workshop. The Kingston Antiphospholipid Antibody Study (KAPS) Group [special report]. Am J Clin Pathol 1990;94:474-84.
25. Parkinson JF, Vlahos CJ, Yan SCU, Bang NU. Recombinant human thrombomodulin. Regulation of cofactor activity and anticoagulant function by a glycosaminoglycan side chain. Biochem J 1992;283:151-7.
26. Atkinson MA, Bowman MA, Kao KJ, et al. Lack of immune responsiveness to bovine serum albumin in insulin-dependent diabetes. N Engl J Med 1993;329:1853-8.
27. Love PE, Santoro SA. Antiphospholipid antibodies. Anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Intern Med 1992;112:682-98.
28. Gastineau DA, Kazmier FJ, Nichols WL, Bowie EJ, Walter L. Lupus anticoagulant. An analysis of the clinical and laboratory features of 219 cases. Am J Hematol 1985;19:265-75.
29. Triplett DA, Brandt JT, Kaczor D, Schaeffer J. Laboratory diagnosis of lupus inhibitors: a comparison of the tissue thromboplastin inhibition procedure with a new platelet neutralization procedure. Am J Clin Pathol 1983;79:678-2.
30. Brandt JT, Triplett DA, Musgrave K, Orr C. The sensitivity of different coagulation reagents to the presence of lupus anticoagulants. Arch Pathol Lab Med 1987;111:120-4.
31. Roubey RAS. Autoantibodies to phospholipid-binding plasma proteins: A new view of lupus anticoagulants and other "antiphospholipid" autoantibodies. Blood 1994;84:2854-67.
32. Cariou R, Tobelem G, Soria C, Caen J. Inhibition of protein C activation by endothelial cells in the presence of lupus anticoagulant. N Engl J Med 1986;314:1193-4.
33. Dittman WA, Majerus PW. Structure and function of thrombomodulin: a natural anticoagulant. Blood 1990;75:329-36.
34. Esmon CT, Snow TR. Inflammation and coagulation: linked processes potentially regulated through a common pathway mediated by protein C. Thromb Haemost 1991;66:160-5.
35. Ruiz-Arguelles GJ, Ruiz-Arguelles A, Alarcon-Segovia D, et al. Natural anticoagulants in systemic lupus erythematosus. Deficiency of protein S bound to C4bp associates with recent history of venous thrombosis, antiphospholipid antibodies, and the antiphospholipid syndrome. J Rheumatol 1991;18:552-8.
36. Stankiewicz AJ, Steiner M, Lally EV, Kaplan SR. Abnormally high level of C4b binding protein and deficiency of free fraction of protein S in a patient with systemic lupus erythematosus and recurrent thromboses. J Rheumatol 1991;18:82-7.
37. Ishii H, Uchiyama H, Kazama M. Soluble thrombomodulin antigen in conditioned medium is increased by damage of endothelial cells. Thromb Haemost 1991;65:618-23.
38. Takano S, Kimura S, Ohdama S. Aoki N. Plasma thrombomodulin in health and diseases. Blood 1990;76:2024-9.
39. Boehme MWJ, Nawroth PP, Kling E. et al. Serum thrombomodulin. A novel marker of disease activity in systemic lupus erythematosus. Arthritis Rheum 1994;37:572-7.
40. Karmochkine M, Boffa MC, Piette JC, et al. Increase in plasmal thrombomodulin in lupus erythematosus with antiphospholipid antibodies. Blood 1992;79:837-8.
41. Solis MM, Cook C, Cook J, et al. Intravenous recombinant soluble human thrombomodulin prevents venous thrombosis in a rat model. J Vasc Surg 1991;14:599-604.
42. Kumada T, Dittman WA, Majerus PW. A role for thrombomodulin in the pathogenesis of thrombin-induced thromboembolism in mice. Blood 1987;71:728-33.
43. Koyama T, Parkinson JF, Aoki N, Bang NU, Muller-Berghaus G, Preissner KT. Relationship between post-translational glycosylation and anticoagulant function of secretable recombinant mutants of human thrombomodulin. Br J Haematol 1991;78:515-22.
44. James JA, Gross T, Scofield RH, Harley JB. Immunoglobulin epitope spreading and autoimmune disease after peptide immunization: Sm B/B′-derived PPPGMRPPand PPPGIRGP induce spliceosome autoimmunity. J Exp Med 1995;181:453-61.
45. Healy AM, Hancock WW, Christie PD, Rayburn HB, Rosenberg RD. Intravascular coagulation activation in a murine model of thrombomodulin deficiency: effects of lesion size, age, and hypoxia on fibrin deposition. Blood 1998;92:4188-97.
46. Healy AM, Rayburn HB, Rosenberg RD, Weiler H. Absence of the blood-clotting regulator thrombomodulin causes embryonic lethality in mice before development of a functional cardiovascular system. Proc Natl Acad Sci USA 1995;92:850-4.
47. Weiler-Guettler H, Christie PD, Beeler AM, et al. A targeted point mutation in thrombomodulile mice with a prethrombotic state. J Clin Invest 1998;101:1983-91.
48. Brisson C, Archipoff G, Hartmann M, et al. Antibodies to thrombomodulin induce receptor-mediated endocytosis in human saphenous vein endothelial cells. Thromb Haemost 1992; 68:737-43.